Unichem Laboratories' Q1 FY 2025-26 Quarter Results

Result Summary

• Unichem Laboratories Ltd reported a 21.8% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Jun (Q1 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 18.5%.
• Its expenses for the quarter were up by 23.8% QoQ and 24.6% YoY.
• The net profit decreased 91.9% QoQ and decreased 213.1% YoY.
• The earnings per share (EPS) of Unichem Laboratories Ltd declined at 1.5 during Q1 FY 2025-26.

Financial Statments for Q1 FY 2025-26

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Unichem Laboratories Ltd is a pharmaceutical company engaged in the development, manufacture, and marketing of a wide range of pharmaceutical formulations. The company operates in the healthcare industry, focusing on providing high-quality medications across various therapeutic segments. Unichem Laboratories has a strong presence in both domestic and international markets, with a diversified product portfolio that includes tablets, capsules, injectables, and other pharmaceutical products. Any recent major developments in the company or industry are not available in the provided data.

Revenue

For the first quarter of the fiscal year 2026 (Q1FY26), Unichem Laboratories Ltd reported a total income of ₹533.42 crore. This reflects a significant quarter-over-quarter (QoQ) increase of 21.8% from ₹437.85 crore in the previous quarter (Q4FY25). On a year-over-year (YoY) basis, total income grew by 18.5% compared to ₹450.29 crore in the first quarter of the previous fiscal year (Q1FY25). The company has shown a robust improvement in revenue generation as evidenced by the growth percentages over both periods.

Profitability

The financial data indicates that Unichem Laboratories Ltd recorded a loss in profitability for Q1FY26. The company reported a loss before tax of ₹9.02 crore, which is a significant improvement from the previous quarter's loss of ₹125.87 crore, marking a substantial decrease of 92.8% in losses QoQ. However, compared to a profit before tax of ₹15.00 crore in Q1FY25, the company experienced a decline of over 160.1% YoY. After accounting for taxes, the profit after tax was a loss of ₹10.47 crore, compared to a loss of ₹129.31 crore in the previous quarter and a profit of ₹9.26 crore in the same quarter last year. The earnings per share (EPS) for Q1FY26 was negative at ₹-1.50, an improvement from the previous quarter's ₹-18.40, but a decline from the positive ₹1.30 in Q1FY25.

Operating Metrics

The total expenses for Unichem Laboratories Ltd in Q1FY26 amounted to ₹542.44 crore, showing an increase of 23.8% QoQ from ₹438.10 crore in Q4FY25 and a 24.6% rise YoY from ₹435.30 crore in Q1FY25. The company observed a substantial increase in expenses over both timeframes. The tax expense for Q1FY26 was ₹1.45 crore, a decrease of 57.8% QoQ from ₹3.44 crore in Q4FY25 and a 74.7% drop YoY from ₹5.74 crore in Q1FY25. The reduction in tax expenses indicates a change in the company's tax obligations during the period. The financial data provided does not include specific information on other financial ratios or metrics such as P/E ratio, debt-to-equity ratio, or current ratio, which can offer further insight into the company's operational performance.